What If CTCL Was Diagnosed After Stopping Dupixent?
Some patients used Dupixent, later stopped treatment, and were diagnosed with CTCL, mycosis fungoides, Sézary syndrome, PTCL, or another related T-cell lymphoma afterward. A diagnosis made after stopping Dupixent does not automatically answer whether further review may be appropriate. The complete symptom, treatment, and diagnosis timeline may matter.
Why Timing Matters in a Dupixent CTCL Review
An initial review may consider when Dupixent treatment began and ended, why it was prescribed, when symptoms appeared or changed, and when a CTCL-related diagnosis was made. The amount of time between these events may help clarify the sequence, but timing alone does not establish what caused a diagnosis.
Lawsuits allege that Dupixent may have caused or accelerated CTCL in some patients and raise questions about warnings and diagnosis. These allegations remain disputed and involve legal and scientific issues that are specific to each person’s history.
For broader background, read Dupixent and CTCL, the Dupixent Lawsuit Overview, and Dupixent litigation updates.
Diagnosis After Stopping Does Not Automatically Answer the Question
A CTCL-related diagnosis after Dupixent was stopped does not automatically qualify or disqualify someone for further review. It also does not prove that Dupixent caused the diagnosis or that the diagnosis is unrelated to the medication.
A diagnosis date may reflect when testing and specialist evaluation confirmed the condition. It may not, by itself, show when the disease began or explain earlier skin symptoms. An initial review may therefore consider the broader medical history rather than relying on the diagnosis date alone.
What Review May Look At
An initial review may consider information such as:
- Why Dupixent was prescribed and the condition being treated
- Approximate Dupixent start and stop dates
- Why treatment was stopped, if documented
- Symptoms before, during, and after Dupixent treatment
- The date and type of CTCL or related T-cell lymphoma diagnosis
- The time between the last Dupixent dose and diagnosis
- Biopsy, pathology, dermatology, oncology, and pharmacy records
- Where treatment and diagnosis occurred and whether another attorney is involved
No single item determines whether follow-up is appropriate. Review depends on the complete medical and legal history.
Symptoms, Biopsies, and Treatment Timeline
CTCL can sometimes resemble eczema, dermatitis, or another inflammatory skin condition, particularly in its earlier stages. A person may have experienced persistent or changing skin symptoms before Dupixent was stopped, even if the CTCL-related diagnosis came later.
Dermatology notes, biopsy dates, pathology findings, and specialist evaluations may help clarify what symptoms were present and when. Repeat biopsies or later pathology review may also matter in some histories.
Learn more about why earlier skin symptoms may be relevant in Was Dupixent Prescribed for Eczema Before a CTCL Diagnosis?
Records That May Help Clarify the Sequence
A person does not need every record before requesting an initial review. If available, these materials may help clarify the sequence:
- Dupixent prescription and pharmacy history
- Records showing approximate treatment start and stop dates
- Dermatology notes from before, during, and after treatment
- Skin photographs and notes describing symptom changes, if available
- Biopsy and pathology reports, including repeat reviews
- Diagnosis records for CTCL, mycosis fungoides, Sézary syndrome, PTCL, or another T-cell lymphoma
- Oncology, hematology, and other specialist records
- A simple written timeline of symptoms, treatment, stopping Dupixent, testing, and diagnosis
Additional guidance is available in the resource on records that may help with a Dupixent CTCL review.
Request an Initial Review
If you or a family member used Dupixent and were later diagnosed with CTCL, mycosis fungoides, Sézary syndrome, PTCL, or another related T-cell lymphoma, you may request an initial review.
You may use the free case review form to provide basic information. Submitting information does not create an attorney-client relationship, does not mean the matter has been accepted, and does not guarantee any particular outcome. This page is for informational purposes only and does not provide legal or medical advice.
Sources reviewed
- JPML and court materials concerning Dupixent CTCL litigation allegations
- Dupixent prescribing information
- FDA and regulatory materials
- Medical literature discussing CTCL, symptom history, and diagnostic evaluation
Last reviewed: June 15, 2026
Request an Initial Review
If you or a family member used Dupixent and were later diagnosed with CTCL, mycosis fungoides, Sézary syndrome, PTCL, or another related T-cell lymphoma, you may request an initial review.